SEC Form 4 · accession 0001209191-15-010844
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mihael Hristos Polymeropoulos
Officer — President and CEO · Director
Period of report
Feb 5, 2015
Accepted (ET)
Feb 9, 2015 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2015 | M | 48,154 | $0.0331 | A | 552,018 | D | |
| Common StockF1 | Feb 5, 2015 | F | 24,947 | $11.28 | D | 527,071 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $0.331 | Feb 5, 2015 | M | 48,154 | D | — | Feb 10, 2015 | Common Stock | 48,154 | 0 | D |
Explanation of responses
- F123,533 shares of the Issuer's common stock were withheld to pay taxes and 1,414 shares of the Issuer's common stock were withheld to pay the option exercise price.
- F2Exercisable with respect to 25% of the shares one year after the grant, exercisable with respect to an additional 2.08333% of the aggregate shares each month thereafter.